Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) announced on Tuesday that it has completed the acquisition of Mirati Therapeutics, Inc. (MRTX), a commercial-stage biotechnology company, in a deal worth up to $5.8 billion.
The acquisition will bring in Mirati's commercialized lung cancer medicine KRAZATI and other clinical assets.
The transaction will be accretive to the company's adjusted earnings per share by around $0.35 per share in 2024.
In the pre-market activity, Bristol Myers Squibb's stock is climbing 0.06 percent, to $49.60 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.